| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Barricaid | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.99M | Series V | 7/14/2026 | $25M | $115.7M | $0.66 | Undisclosed Investors | ||||
 | Bluejay Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $242.24M | Series C-1 | 5/9/2024 | $1.14M | $371.77M | $6.53 | Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital | ||||
 | Dispatch Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.79M | Series A | 7/23/2025 | $114M | $270.29M | $3.04 | ARCH Venture Partners, PICI, Bristol Myers Squibb, University of Pennsylvania, Stanford University, Alexandria Venture Investments | ||||
 | EndoQuest Robotics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.22M | Series D-2 | 7/14/2025 | $30.74M | $316.22M | $0.80 | Crescent Enterprises, Dr. Fred Moll, Puma Venture Capital, UTHealth Houston | ||||
 | Epic Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $606.66M | Series A-3 | 12/29/2023 | $20.9M | $94.14M | $3.00 | Undisclosed Investors | ||||
 | Farcast Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $79.8M | Series B | 7/11/2018 | $73.28M | $153.24M | $0.35 | Northpond Ventures, Accel, Sequoia Capital, Sands Capital Ventures, RA Capital Management | ||||
 | Hotspot Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $380.54M | Series C | 11/29/2021 | $100.14M | $300.77M | $3.24 | Pivotal bioVenture Partners, LSP, B Capital Group, Monashee Investment Management, CaaS Capital Management, Revelation Partners, Pavilion Capital, Atlas Venture, Sofinnova Partners, SR One Capital Management, Tekla Capital Management, MRL Ventures Fund | ||||
 | Inquis Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $141.46M | Series C | 1/12/2026 | $75M | $370.67M | $0.86 | Undisclosed Investor | ||||
 | Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B | 9/7/2023 | $175M | $311.65M | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | ||||
 | Memora Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.4M | Series A-1 | 4/18/2023 | $30M | $420M | $3.22 | General Catalyst, Northwell Holdings, NorthShore, Edward Elmhurst Health, PagsGroup, Andreessen Horowitz, Transformation Capital, Frist Cressey Ventures | ||||
 | Mission Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $183M | Series B-1 | 8/5/2025 | $40M | $210.45M | $1.00 | Ally Bridge Group | ||||
 | myLaurel | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $5M | Series A | 11/6/2025 | $4.12M | $35.62M | $1.29 | SteelSky Ventures, GV, Deerfield Management | ||||
 | Nikang Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260.25M | Series C | 5/26/2021 | $200M | $475.12M | $5.74 | Cormorant Asset Management, HBM Healthcare Investments, Octagon Capital Advisors, EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavillion Capital, BlackRock, RA Capital Management, Surveyor Capital, Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, Logos Capital, CBC Group, RTW Investments, Lilly Asia Ventures, Matrix Partners China, Casdin Capital | ||||
 | OrsoBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.63M | Series B | 9/6/2024 | $67M | $316.32M | $0.71 | Ascenta Capital, Woodline Partners, Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, Eli Lilly and Company | ||||
 | Pearl Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.27M | Series C | 7/8/2026 | $50M | $284.96M | $0.67 | Andreessen Horowitz, Viking Global Investors, AlleyCorp, Ulysses Capital, Gaingels, Alumni Ventures | ||||
 | Relievant Medsystems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.66M | Series G | 3/17/2023 | $50M | $361.21M | $0.11 | Undisclosed Investors | ||||
 | SPR Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.49M | Series D-1 | 2/1/2024 | $25.64M | $263.67M | $27.44 | Revelation Partners, RC Capital, Mutual Capital Partners | ||||
 | Stepful | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $103.91M | Series C | 6/8/2026 | $52.97M | $475.35M | $26.68 | Oak HC/FT, Foresite Capital, Hearst Ventures, Citi, SemperVirens, Y Combinator, Intermountain Health, ECMC Group | ||||
 | Supira Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $241.09M | Series E | 3/26/2025 | $120M | $431.99M | $1.35 | Novo Holdings, Qatar Investment Authority, Cormorant Asset Management, TCP, 415 Capital, AMED Ventures, Picard Angst, Unorthodox Ventures | ||||
 | Tetherex Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.65M | Series B | 4/18/2018 | $63.95M | $366.68M | $21.32 | MPM Capital, Philip Jones | ||||
 | Tome Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $245.57M | Series B | 12/12/2023 | $150M | $435.54M | $3.03 | Andreessen Horowitz, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments | ||||
 | Aerin Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $172.7M | Series G | 1/13/2025 | $32.82M | $342.42M | $1.17 | KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group, Ares Capital | ||||
 | AiTA | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $25.63M | Series C | 1/14/2025 | $10M | $317.19M | $5.05 | Undisclosed Investors | ||||
 | Alveus Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $202.01M | Series A | 2/24/2026 | $197M | $290.11M | $20.00 | New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego Management, Jeito Capital, Novo Holdings, Agent Capital, Seroba Lifesciences, Global BioAccess Fund | ||||